Detalles de la búsqueda
1.
Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Blood
; 117(6): 1947-57, 2011 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21148814
2.
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
Blood
; 118(19): 5189-200, 2011 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21911831
3.
Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.
J Biol Chem
; 286(39): 34036-50, 2011 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-21816815
4.
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Blood
; 115(22): 4478-87, 2010 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-20233973
5.
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Br J Haematol
; 153(2): 222-35, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21375523
6.
IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms.
Blood Adv
; 5(19): 3776-3788, 2021 10 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34464977
7.
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Blood
; 112(6): 2439-49, 2008 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18614762
8.
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Clin Cancer Res
; 14(2): 549-58, 2008 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18223231
9.
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
J Hematol Oncol
; 12(1): 25, 2019 03 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30845975
10.
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Clin Cancer Res
; 12(7 Pt 1): 2239-47, 2006 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16609040
11.
The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Cancer Res
; 64(7): 2590-600, 2004 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15059916
12.
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Clin Cancer Res
; 8(7): 2123-33, 2002 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12114412
13.
Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis.
Biochem Pharmacol
; 65(12): 1997-2008, 2003 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12787880
14.
Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
PLoS One
; 9(3): e89064, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24594907
15.
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Cancer Res
; 72(16): 4225-37, 2012 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22693249
16.
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Clin Cancer Res
; 17(10): 3219-32, 2011 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21474579
17.
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
Cancer Biol Ther
; 8(9): 808-19, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19270531
18.
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Mol Pharmacol
; 70(2): 645-55, 2006 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16672643
19.
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Mol Pharmacol
; 67(4): 1166-76, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15625278
Resultados
1 -
19
de 19
1
Próxima >
>>